$VCYT News

Veracyte: Diagnostics With Favorable Economics

Veracyte: Core Growth Funds Prosigna And TrueMRD

Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential

Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54

Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $55

Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44

Canaccord Genuity Maintains Hold on Veracyte, Lowers Price Target to $50

Veracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation

Needham Maintains Buy on Veracyte, Raises Price Target to $69

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript

Veracyte (NASDAQ:VCYT) Smashes Q2 Estimates but Full-Year Guidance Disappoints, Shares Fall

Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est

Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance

Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout Setup

Piper Sandler Initiates Coverage On Veracyte with Overweight Rating, Announces Price Target of $66

Canaccord Genuity Maintains Hold on Veracyte, Raises Price Target to $60

Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $47

Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profile

Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65

High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT)